- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Drisapersen
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 5 Years to 80 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 2,286
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- HOE901-U300 (Insulin glargine new formulation), Lantus (Insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 82
- States / cities
- Chandler, Arizona • Little Rock, Arkansas • Bell Gardens, California + 71 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Vamorolone
- Drug
- Lead sponsor
- Santhera Pharmaceuticals
- Industry
- Eligibility
- Male only
- U.S. locations
- 6
- States / cities
- Davis, California • Orlando, Florida • Chicago, Illinois + 3 more
- Conditions
- Alcohol Dependence
- Interventions
- XR-NTX (Extended-Release Naltrexone), Oral Naltrexone (O-NTX)
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Osteoarthritis, Knee
- Interventions
- FX006 32 mg
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- El Cajon, California • La Mesa, California • Pomona, California + 5 more
- Conditions
- Epilepsy
- Interventions
- Ezogabine: USAN Retigabine (International Nonproprietary Name)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 25 more
- Conditions
- Ulcerative Colitis
- Interventions
- Mirikizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,058 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 48
- States / cities
- Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 41 more
- Conditions
- Myositis, Dermatomyositis
- Interventions
- Deucravacitinb
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Canavan Disease
- Interventions
- rAAV-Olig001-ASPA, Levetiracetam, Prednisone
- Drug
- Lead sponsor
- Myrtelle Inc.
- Industry
- Eligibility
- 3 Months to 60 Months
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Dayton, Ohio
- Conditions
- HIV Infections
- Interventions
- Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, Cabotegravir, Rilpivirine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 16
- States / cities
- San Francisco, California • DeLand, Florida • Fort Lauderdale, Florida + 12 more
- Conditions
- Tay-Sachs Disease, Sandhoff Disease
- Interventions
- venglustat GZ402671, placebo
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Atlanta, Georgia • Bethesda, Maryland + 2 more
- Conditions
- Hypertension, Pulmonary
- Interventions
- Sotatercept
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • La Jolla, California • Santa Barbara, California + 20 more
- Conditions
- Amyloidosis
- Interventions
- Patisiran
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 14
- States / cities
- La Mesa, California • Aurora, Colorado • Jacksonville, Florida + 10 more
- Conditions
- Hypercholesterolemia
- Interventions
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 44
- States / cities
- Huntsville, Alabama • Tempe, Arizona • Bell Gardens, California + 39 more
- Conditions
- Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy
- Interventions
- SBR759, Sevelamer HCl
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 19
- States / cities
- Chula Vista, California • La Mesa, California • Whittier, California + 16 more
- Conditions
- Healthy
- Interventions
- 1 tablet Empagliflozin/2 tablets Metformin XR, 10 mg Empagliflozin/1000 mg Metformin XR, 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR, 2 tablets 5 mg Empagliflozin/750 Metformin XR
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Hypertension
- Interventions
- aliskiren
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Solid Tumors
- Interventions
- Idasanutlin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • New Haven, Connecticut • St Louis, Missouri + 5 more
- Conditions
- Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects
- Interventions
- KB109, No intervention
- Other
- Lead sponsor
- Kaleido Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 8
- States / cities
- Torrance, California • Atlanta, Georgia • Augusta, Georgia + 5 more
- Conditions
- Oral Lichen Planus
- Interventions
- Pimecrolimus 1% cream
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Depressive Disorder, Major
- Interventions
- Mifepristone
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 13
- States / cities
- San Diego, California • Atlanta, Georgia • Las Vegas, Nevada + 10 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- dutogliptin
- Drug
- Lead sponsor
- Phenomix
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 27
- States / cities
- Fullerton, California • Long Beach, California • Orange, California + 24 more
- Conditions
- Opioid Use Disorder, Opioid-related Disorders
- Interventions
- RBP-6000
- Drug
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 29
- States / cities
- Hamilton, Alabama • Little Rock, Arkansas • Long Beach, California + 25 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Adalimumab, Placebo
- Biological · Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 619 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2010
- U.S. locations
- 76
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more